ClinicalTrials.gg
CompletedNCT04936178Updated Dec 22, 2025

A Study of NB003 in Patients With Advanced Malignancies

A Phase 1 interventional study of NB003 tablets in Advanced Solid Tumor, sponsored by Ningbo Newbay Technology Development Co., Ltd. Completed at 32 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-22.

Sponsored by Ningbo Newbay Technology Development Co., Ltd · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Aug 2025, 1 year 3 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
258
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This a A Phase 1, Open-label, Multicenter Study to Assess the Safety, Tolerability, and Pharmacokinetics of NB003 in Subjects with Advanced Malignancies

Read the detailed description

This is a phase 1, open-label, multicenter study of NB003 which comprised of a dose escalation phase to determine the MTD or maximum administered dose (MAD), and the RP2D and a dose expansion phase to further explore the safety, PK and efficacy of NB003.

The dose escalation phase will enroll patients with advanced gastrointestinal stromal tumor (GIST) who have progressed on or had an intolerability to imatinib and other standard of cares (SoCs) or refused other SoCs, and patients with advanced malignancies other than GIST that harbors KIT or PDGFRα gene alterations who have relapsed or have refractory disease without an available effective therapy. The number of patients to be enrolled during the dose escalation part will vary depending on the underlining dose-toxicity curve and the number of dose levels tested prior to reaching MTD or MAD. After the MTD or MAD has been determined, based on emerging safety/PK data, one or more putative RP2D(s) will be explored in dose escalation phase with approximately 15 patients for each provisional RP2D(s) to establish the RP2D for dose expansion phase. This step will be regarded as RP2D confirmation part of dose escalation phase.

In the dose expansion phase, additional patients will be enrolled to further explore the safety, tolerability, PK, efficacy and biological activity of NB003 in specific disease cohorts, including GIST and other malignancies harboring genomic alterations of KIT or PDGFRα. Dose expansion phase is planned to investigate NB003 at the RP2D determined from dose escalation phase.

02

Conditions studied

  • Advanced Solid Tumor
03

In context

Lead sponsor

Ningbo Newbay Technology Development Co., Ltd is the lead sponsor of 3 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males or females of any race ≥18 years age.
  2. -confirmed diagnosis of unresectable, or GIST or other advanced .

    1. For dose escalation phase:

      • GIST patients must have progressed on or had an intolerability to imatinib and other SoCs or refused other SoCs.
      • Patients with an advanced solid tumor other than GIST must have relapsed or had refractory disease without an available effective therapy and harbor KIT or PDGFRα gene alterations (central laboratory confirmation is not required for screening).
    2. For dose expansion phase:

    Cohort 1: GIST patients with KIT or PDGFRα gene mutations, must have progressed on or been intolerant to at least imatinib, sunitinib, regorafenib and ripretinib (≥ fifth line therapy setting); Cohort 2a: GIST patients with KIT or PDGFRα gene mutations, must have progressed on or been intolerant to imatinib and sunitinib, and who have not received additional systemic therapy for advanced GIST ( therapy setting); Cohort 2b: GIST patients with KIT or PDGFRα gene mutations, must have progressed on or been intolerant to imatinib, sunitinib and regorafenib, and who have not received additional systemic therapy for advanced GIST (forth line therapy setting); Cohort 3: GIST patients with KIT or PDGFRα gene mutations, must have progressed on or been intolerant to imatinib and have not received additional systemic therapy for advanced GIST (second line therapy setting); Cohort 4: GIST patients with PDGFRα exon 18 mutation and must have progressed on or been intolerant to avapritinib; in the countries/regions where avapritinib is not SoC, avapritinib-naïve patients can be enrolled; Cohort 5: Unresectable or metastatic melanoma patients with demonstrated evidence for KIT gene mutation and/or amplification, must have progressed on or been intolerant to SoCs; Cohort 6: Patients with other advanced malignancies other than GIST or melanoma which must be relapsed or refractory without an available effective therapy and harbor KIT or PDGFRα gene alterations.

  3. For dose expansion phase: at least one per v1.1/.
  4. (ECOG) performance status of 0 or 1.
  5. ≥ 12 weeks.
  6. Adequate organ and marrow function.
  7. Tumor sample collection is required.

Exclusion criteria

Exclusion Criteria:

  1. Prior anti-cancer therapy within 2 weeks or at least 5 half-lives, whichever is longer, up to a maximum of 21 days prior to the initiation of study drug administration.
  2. Major surgery within 4 weeks of the first dose.
  3. Radiotherapy with a limited field of radiation for palliation within 1 week prior to the first dose, with the exception as defined.
  4. Patients currently receiving medications or herbal supplements known to be strong inhibitors or inducers of .
  5. Patients currently receiving acid-reducing agents and are unable to stop use at least 2 weeks prior to the first dose.
  6. Any known active central nervous system and/or carcinomatous meningitis. Active infection including , , and .
  7. Any other comorbidities, such as uncontrolled pulmonary disease, active infection, uncontrolled pericardial effusion, uncontrolled pleural effusion, or any other conditions, which in the judgment of Investigator, could compromise compliance with the protocol, interfere with the interpretation of study results, or predispose the patient to safety risks.
  8. Any evidence of severe or uncontrolled systemic diseases which in the Investigator's opinion makes it undesirable for the patient to participate in the trial or which would jeopardize compliance with the protocol.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

iRECIST and mRECIST

Versions of RECIST adapted to particular cases. iRECIST is for immunotherapy, where a tumor can look bigger for a while before it shrinks, so growth has to be confirmed on a later scan. mRECIST usually means the version for liver cancer (hepatocellular carcinoma), which measures only the part of a tumor that still has a blood supply.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
258 participants (actual)

Study arms

  • Experimental
    Dose Escalation Phase and Dose Expansion Phase

    Dose escalation cohort: NB003 tablets will be administered orally twice daily for repeated 28-day cycles until discontinuation criteria are met. RP2D: one or more putative RP2D(s) will be explored in dose escalation phase with approximately 15 patients for each provisional RP2D(s) Dose expansion phase: In the dose expansion phase, additional patients will be enrolled at RP2D to further explore the safety, tolerability, PK, efficacy and biological activity of NB003 in specific disease cohorts, including GIST and other malignancies harboring genomic alterations of KIT or PDGFRα.

    Drug: NB003 tablets

Interventions

  • DrugNB003 tablets

    NB003 tablets will be administered at assigned doses for escalation phase and RP2D doses for expansion phase orally twice daily for repeated 28-day cycles until discontinuation criteria are met.

06

What researchers measure

Primary outcomes

  1. Incidence of dose-limiting toxicities

    Dose Escalation Phase:Dose-limiting toxicities will be reviewed as a subset of adverse events that occur within the first 28 days of dosing and meet protocol-specified criteria.

    Time frame: Approximately 24 months since the escalation first subject enrolled

  2. Incidence of adverse events

    Dose Escalation Phase and Dose Expansion Phase: An AE is any untoward medical occurrence in a participant who received study drug without regard to causal relationship.

    Time frame: Approximately 24 months since the escalation first subject enrolled; Approximately 26 months since the Expansion first subject enrolled

  3. Objective Response Rate (ORR)

    Dose Expansion Phase: Objective Response Rate (ORR) which is defined as the percentage of patients whose efficacy is confirmed as complete response(CR) or partial responses(PR)

    Time frame: Approximately 26 months since the Expansion first subject enrolled

  4. Duration of Response(DOR)

    Dose Expansion Phase: DOR is defined as the time from the date of first documented response until date of documented progression, for subjects who achieve CR or PR.

    Time frame: Approximately 26 months since the Expansion first subject enrolled.

Secondary outcomes

  1. Area under the curve (AUC) from time zero to the last measurable concentration AUC (0-t)

    Dose Escalation Phase and Dose Expansion Phase: AUC (0-t) = Area under the serum concentration versus time curve from time zero (pre-dose) to the time of the last measurable concentration.

    Time frame: Approximately 24 months since the escalation first subject enrolled; Approximately 26 months since the Expansion first subject enrolled

  2. Maximum observed plasma concentration (Cmax)

    Dose Escalation Phase and Dose Expansion Phase: Maximum observed plasma concentration (Cmax)

    Time frame: Approximately 24 months since the escalation first subject enrolled; Approximately 26 months since the Expansion first subject enrolled

  3. Time to Cmax (Tmax)

    Dose Escalation Phase and Dose Expansion Phase: Time to Cmax (Tmax)

    Time frame: Approximately 24 months since the escalation first subject enrolled; Approximately 26 months since the Expansion first subject enrolled

  4. Terminal elimination half life

    Dose Escalation Phase and Dose Expansion Phase: Terminal elimination half life

    Time frame: Approximately 24 months since the escalation first subject enrolled; Approximately 26 months since the Expansion first subject enrolled

  5. Objective Response Rate (ORR)

    Dose Escalation Phase: Objective Response Rate (ORR) which is defined as the percentage of patients whose efficacy is confirmed as complete response(CR) or partial responses(PR)

    Time frame: Approximately 24 months since the escalation first subject enrolled

  6. Duration of Response(DOR)

    Dose Escalation Phase: DOR is defined as the time from the date of first documented response until date of documented progression, for subjects who achieve CR or PR.

    Time frame: Approximately 24 months since the escalation first subject enrolled

Other outcomes

  1. Cancer relevant gene mutations

    Dose Escalation Phase and Dose Expansion Phase:Cancer relevant gene mutations

    Time frame: Approximately 24 months since the escalation first subject enrolled; Approximately 26 months since the Expansion first subject enrolled

07

Study locations

32 sites
  • Standford University
    Stanford, California 32224, United States
  • Mayo Clinic
    Jacksonville, Florida 32224, United States
  • Dana-Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • Memorial Sloan Kettering Cancer Center
    Long Island City, New York 11101, United States
  • Oregon Health & Science University (OHSU)
    Portland, Oregon 97239, United States
  • U T MD Anderson Cancer Center Investigational Pharmacy Services
    Houston, Texas 77030, United States
  • The Second Hospital of Anhui Medical University
    Hefei, Anhui 230601, China
  • Beijing Cancer Hospital
    Beijing, Beijing Municipality 100142, China
  • Peking University People's Hospital
    Beijing, Beijing Municipality 100144, China
  • The First Affiliated Hospital of Chongqing Medical University
    Chongqing, Chongqing Municipality 400016, China
  • Fujian Cancer Hospital
    Fuzhou, Fujian 350015, China
  • Sun Yat-sen University Cancer Center
    Guangzhou, Guandong 510000, China
  • The First Affiliated Hospital of Sun Yat-sen University
    Guangzhou, Guandong 510080, China
  • Harbin Medical University Cancer Hospital
    Harbin, Heilongjiang 150081, China
  • Xiangya Hospital, Central South University
    Changsha, Huanan 410008, China
  • Union Hospital Tongji Medical College Huazhong University of Science and Technology
    Wuhan, Hubei 430022, China
  • The Affiliated Hospital of Nanjing University Medical School
    Nanjing, Jiangsu 210008, China
  • Liaoning Cancer Hospital & Institute
    Shenyang, Liaoning 110042, China
  • The Second Affiliated Hospital of Xi'An Jiaotong University
    Xi'an, Shaanxi 710004, China
  • The Affiliated Hospital of Qingdao University
    Qingdao, Shandong 266003, China
  • Fudan University Shanghai Cancer Center
    Shanghai, Shanghai Municipality 201315, China
  • Renji Hospital Shanghai Jiaotong University School of Medicine - West Branch
    Shanghai, Shanghai Municipality 201315, China
  • West China Hospital, Sichuan University
    Chengdu, Sichuan 610041, China
  • Tianjin Medical University Cancer Institute & Hospital
    Tianjin, Tianjin Municipality 453000, China
  • The First Affiliated Hospital of Zhejiang University school of medicine
    Hangzhou, Zhejiang 310003, China
  • Centre Léon Bérard
    Lyon, Rhone 69373, France
  • Institut Gustave Roussy
    Villejuif, Val de Marne 94805, France
  • Asan Medical Center
    Seoul, Seoul 05505, South Korea
  • Samsung Medical Center
    Seoul, Seoul 05505, South Korea
  • Hospital Universitari Vall d'Hebron
    Barcelona, Barcelona 08035, Spain
  • Hospital Universitario Fundacion Jimenez Diaz
    Madrid, Madrid 28040, Spain
  • Royal Marsden Hospital-London
    London, London SW36JJ, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2021 to primary completion in Aug 2025, 47 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 3, 2021
First posted
Jun 23, 2021
StartActual
Aug 6, 2021
Primary completionActual
Aug 1, 2025
CompletionActual
Aug 1, 2025
Last update
Dec 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04936178
Lead sponsor
Ningbo Newbay Technology Development Co., Ltd
Responsible party
Sponsor
First posted
Jun 23, 2021
Start date
Aug 6, 2021
Primary completion
Aug 1, 2025
Completion
Aug 1, 2025
Last update
Dec 22, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion